Melanoma and Mastocytosis by Vojvodic, Aleksandra et al.
 
_______________________________________________________________________________________________________________________________ 
3050                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Sep 30; 7(18):3050-3052. 
https://doi.org/10.3889/oamjms.2019.772 
eISSN: 1857-9655 
Global Dermatology 
 
 
  
 
Melanoma and Mastocytosis 
 
 
Aleksandra Vojvodic
1
, Tatjana Vlaskovic-Jovicevic
2
, Petar Vojvodic
2
, Jovana Vojvodic
2
, Mohamad Goldust
3
, Zorica Peric-
Hajzler
4
, Dusica Matovic
4
, Goran Sijan
5
, Nenad Stepic
5
, Uwe Wollina
6
, Massimo Fioranelli
7*
, Michael Tirant
8
, Van Thuong 
Nguyen
9
, Torello Lotti
10
 
 
1
Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia; 
2
Clinic for Mental Disorders “Dr 
Laza Lazarevic” Belgrade, Serbia; 
3
Guglielmo Marconi University, Rome, Italy; 
4
Military Medical Academy, Belgrade, Serbia; 
5
Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia; 
6
Department of Dermatology and 
Allergology, Städtisches Klinikum Dresden, Dresden, Germany; 
7
Department of Nuclear Physics, Sub-nuclear and 
Radiation, G. Marconi University, Rome, Italy; 
8
University G. Marconi, Rome, Italy; 
9
Vietnam National Hospital of 
Dermatology and Venereology, Hanoi, Vietnam; 
10
Department of Dermatology, Guglielmo Marconi University, Rome, Italy 
 
Citation: Vojvodic A, Vlaskovic Jovicevic T, Vojvodic P, 
Vojvodic J, Goldust M, Peric Hajzler Z, Matovic D, Sijan 
G, Stepic N, Wollina U, Fioranelli M, Tirant M, Thuong 
Nguyen V, Lotti T. Melanoma and Mastocytosis. Open 
Access Maced J Med Sci. 2019 Sep 30; 7(18):3050-3052. 
https://doi.org/10.3889/oamjms.2019.772 
Keywords: Melanoma; Mastocytosis; Growth factor; 
Mastocytoma 
*Correspondence: Massimo Fioranelli. Department of 
Nuclear Physics, Sub-nuclear and Radiation, G. Marconi 
University, Rome, Italy. E-mail: 
massimo.fioranelli@gmail.com 
Received: 13-Jun-2019; Revised: 04-Jul-2019; 
Accepted: 05-Jul-2019; Online first: 30-Aug-2019 
Copyright: © 2019 Aleksandra Vojvodic, Tatjana 
Vlaskovic Jovicevic, Petar Vojvodic, Jovana Vojvodic, 
Mohamad Goldust, Zorica Peric Hajzler, Dusica Matovic, 
Goran Sijan, Nenad Stepic, Uwe Wollina, Massimo 
Fioranelli, Michael Tirant, Van Thuong Nguyen, Torello 
Lotti. This is an open-access article distributed under the 
terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
Abstract 
There are numerous cases reports and studies confirming the enhanced incidence of melanoma among patients 
with mastocytosis, especially with systemic mastocytosis. These two diseases are arising from two different types 
of cells; melanoma arises from neural crest cells and mastocytosis from hematopoietic stem cells. But there are a 
lot of similarities between the two diseases. The most important and significant is the dependence of the growth 
factor receptor c‐KIT and c‐KIT ligand (stem cell factor) for their growth and development. Also, expression of the 
STAT3 (signal transducer and activator of transcription 3) and transcription factors MITF 
(microphthalmia‐associated transcription factor) make the connection between melanoma and mastocytosis. 
 
 
 
 
 
 
 
 
 
Introduction 
 
There are numerous cases reports and 
studies confirming the enhanced incidence of 
melanoma among patients with mastocytosis, 
especially with systemic mastocytosis. These two 
diseases are arising from two different types of cells; 
melanoma arises from neural crest cells and 
mastocytosis from hematopoietic stem cells. But there 
are a lot of similarities between the two diseases. The 
most important and significant is the dependence of 
the growth factor receptor c‐KIT and c‐KIT ligand 
(stem cell factor) for their growth and development. 
Also, expression of the STAT3 (signal transducer and 
activator of transcription 3) and transcription factors 
MITF (microphthalmia‐associated transcription factor) 
make the connection between melanoma and 
mastocytosis.  
 
 
Discussion 
 
Mastocytosis is a group of rare disorders 
characterised by the proliferation and accumulation of 
mast cells in the skin and/or other organs, and occur 
in children and adults. Most of the patients, about 
80%, are with cutaneous mastocytosis, and mostly the 
course is indolent (90%). Classification of cutaneous 
mastocytosis is into urticaria pigmentosa, the most 
common cutaneous variant, solitary mastocytoma and 
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diffuse cutaneous mastocytosis. 
Melanoma is one of the most malignant 
cancers, with the incidence increasing all over the 
world, and it is one of the most frequent cancers in 
fair-skinned populations. There are biological 
explanations for an increased incidence of melanoma 
among patients with mastocytosis. Mast cells would 
interact with melanocytes through the release of 
cytokines. The high rate of mutations in melanoma 
makes it difficult to distinguish between driver 
mutations and bystander mutations. The most 
frequent driver mutations in melanoma are BRAF, 
NRAS, KIT, GNAQ, GNA11, NF1 and telomerase). 
BRAF and NRAS mutations are mostly found in 
cutaneous melanomas, and KIT mutations are 
detected in acral and mucosal melanomas. In 
systemic mastocytosis a KIT D816V mutation is 
present in almost all cases, in adult-, but not in 
childhood-onset mastocytosis. This mutation of 
KIT
D816V
 has been found in melanoma, but its 
involvement is yet not well understood. In some 
studies, it is shown that KIT
D816V
 induces tyrosine 
phosphorylation of microphthalmia-associated 
transcription factor (MITF). It forms a triple protein 
complex formation of KIT, MITF, and SRC family 
kinases. Activated microphthalmia-associated 
transcription factor activates genes involved in 
melanoma proliferation, cell-cycle progression, 
survival, and also an invasion. Both mast cells and 
melanocytes need for growth binding of the stem cell 
factor (SCF) to the KIT receptor. The SCF receptor is 
expressed in primitive hematopoietic cells and mast 
cells mostly, but it is also expressed in certain regions 
of the brain, germs cells, melanocytes and basal cells 
in the skin, interstitial cells of Cajal. The signalling 
pathways activated downstream from Kit receptor 
include MAP kinase pathways, Src kinases, PI3-
kinase and phospholipase C and D. Mast cells are 
producing large subsets of mediators (e.g., EGF, 
NGF, PDGF, SCF, angiopoietin, heparin, IL-8, VEGF). 
They are involved in IgE-associated allergic reactions, 
mostly, but numerous studies have shown the 
connection between mast cells accumulation and 
tumour growth – melanoma, Merkel cell carcinoma 
adenocarcinoma, squamous cell carcinomas, prostate 
carcinoma, etc. In mastocytosis, RAF is the most 
frequently mutated kinases, where BRAF V600E 
mutation occurs in most hairy cell leukaemias (HCL) 
and half of the malignant melanomas. Thus, although 
BRAF is commonly mutated, it appears not to be 
present in SM. The risk‐association to other 
hematologic neoplasms and the risk of cardiovascular 
disease in mastocytosis is well‐established, but also 
for increased risk of solid cancer as well as 
thromboembolic morbidity. Mast cells are influencing 
tumour development and remodelling of tissue, 
tumour-induced angiogenesis, and shaping of 
adaptive immune responses to tumours. Mostly 
presence of mast cells in tumours is associated with 
poor prognosis, but for prostate cancer and colorectal 
cancer is a favorable prognostic factor. The use of 
kinase inhibitors could improve cancer treatment, but 
the main problem with this treatment is the second 
mutation in c-Kit, which changes the biding region of 
kinase inhibitor, and the result is drug resistance [1], 
[2], [3], [4], [5], [6]. 
Melanoma inhibitory activity (MIA) is 
expressed on mast cells of cutaneous mastocytosis, 
neurofibroma cells in patients with neurofibromatosis 
type 1 (NF1) and it is used as a serum marker for 
malignant melanoma. The function of MIA is in 
inhibition of apoptosis in melanocytic cells, but the 
whole mechanisms of expression on mast cells are 
unknown. Inhibition of the transcription factor, SOX10 
reduced MIA expression and promoter activity. This 
transcriptional factor is important for melanoma 
development and survival [7], [8]. 
After exposure to histamine, melanocytes 
undergo morphological variations and increased 
activity of tyrosinase. Also, one of the most potent 
mast cell growth factors- CD-117 binding mast cells 
growth factor (MFG) stimulates the proliferation of 
both mast cells and melanocytes.  
One of the therapies mostly used for the 
cutaneous mastocytosis is phototherapy, 311 nm UVB 
and PUVA and it is well known that UV exposure 
favour the onset of skin cancers. 
The role of estrogens on the development of 
melanoma and on the exacerbation of the 
mastocytosis is extremely unknown, but it has been 
shown in vitro that binding estradiol to estrogen 
receptor-α on the membrane of mast cells supports 
the synthesis and release of mast cell mediators [9]. 
In conclusion, there is an enhanced incidence 
of melanoma among patients with mastocytosis, 
especially with systemic mastocytosis, and connection 
between these two diseases is still not clear. 
Understanding the influence of mast cells on 
melanocytes could bring great benefit in threatening 
the melanoma. New studies are needed. 
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